| Literature DB >> 20191864 |
Cătălina Luca1, Lucia Grigore, A Vâţă, Carmen Dorobăţ.
Abstract
Hepatitis C virus infection is estimated to affect over 170 million people worldwide. Standard treatment for chronic HCV involves an interferon-based preparation and ribavirin for 24 to 48 weeks. These therapeutic regimens are associated with numerous adverse events, among which constitutional and neuropsychiatric symptoms, as well as hematological abnormalities, stand out. Adverse events resulting from the treatment of hepatitis C can jeopardize the quality of life of patients and their response to treatment. The control of those events involves medicinal and non-medicinal interventions. The latter include a reduction in the dosage of IFN or RBV and discontinuation of the treatment.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20191864
Source DB: PubMed Journal: Rev Med Chir Soc Med Nat Iasi ISSN: 0048-7848